The Finnish company Deep Sensing Algorithms Oy (DSA) has developed a unique DSA BreathPass™ device for testing COVID-19. The handheld analyzer detects the Covid-19 virus from exhaled air and the diagnosis is established in seconds.
In the autumn of 2020, Tepcomp signed a cooperation agreement with DSA and will be responsible for the manufacture of the device. Manufacture of healthcare devices is the core competence of Tepcomp and the company has the ISO 13485 certificate required for the manufacture of medical devices.
“Tepcomp has many decades of experience and a good reputation in terms of healthcare equipment. The production of the BreathPass™ device involves demanding processes and sensitive technology, but we have full confidence in Tepcomp’s expertise and adherence to strict quality requirements,” says Pekka Rissanen, CEO of DSA.
Since autumn, Tepcomp has been involved in the production of a new device and the NPI (new product introduction) process during which the prototype is processed for production into a final product.
With BreathPass™, COVID-19 testing is faster, more flexible and significantly cheaper. The average sampling time with the device is 15 seconds and the system is ready for a new person every two minutes. BreathPass™ is based on a technology developed by Professor Risto Orava in which the analyser’s nanosensors identify the properties of the person’s breath. The measurement data is transferred to the cloud service via a phone application and the test result is ready in a few seconds.